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‘‘Browning,’’ the appearance and activation of
brown-in-white (brite) adipose cells within inguinal
white adipose tissue (iWAT), and induction of uncou-
pling protein 1 (UCP1) correlate with fibroblast
growth factor-21 (FGF21)-induced weight loss and
glucose homeostasis improvements. Therefore, anti-
obesity therapies targeting browning and brite
adipocyte activation are currently being sought. To
test the dependence of weight loss on browning,
we examined whether this event was responsible
for FGF21-Fc’s beneficial effects. Lean and diet-
induced obese mice housed at 21C or 30C that
received FGF21-Fc exhibited similar degrees of
body weight reduction and glucose homeostasis
improvement. Substantial browning of iWAT oc-
curred only in FGF21-Fc-treated lean mice housed
at 21C. Further, FGF21-Fc-treated Ucp1/ mice
showed robust improvements in body weight,
glucose homeostasis, and plasma lipids, associated
with increased energy expenditure and FGF21-Fc-
induced Ppargc1 expression in iWAT. We conclude
that FGF21 requires neither UCP1 nor brite adipo-
cytes to elicit weight loss and improve glucose
homeostasis.
INTRODUCTION
In mammals, brown adipose tissue (BAT) preserves body
temperature through nonshivering thermogenesis enabled by
release of intracellular BAT lipids during lipolysis and heat gener-
ation in mitochondria via uncoupling protein 1 (UCP1) (Chechi
et al., 2013). There are two types of BAT: classic BAT is derived
from myogenic factor 5 (myf5), a muscle-like cell lineage, pre-
dominantly populating interscapular and subcutaneous regions
in rodents and humans; adaptive BAT (beige or brown-in-white
[brite]) is characterized by a non-myf5-derived lineage express-
ing UCP1 (Giralt and Villarroya, 2013). Brite adipocytes aremulti-
locular lipid-containing cells located in inguinal white adipose
tissue (iWAT; Emanuelli et al., 2014). Cold exposure markedly in-
duces classic BAT and brite adipocytes (Fisher et al., 2012) andCcorrelates with the appearance of UCP1-positive cells in iWAT.
Further, mitochondria from cold-adapted iWAT are functionally
thermogenic (Shabalina et al., 2013) and dependent on UCP1
presence (Nedergaard et al., 2001).
Fibroblast growth factor-21 (FGF21) is an important meta-
bolic regulator (Berglund et al., 2009; Coskun et al., 2008; Khar-
itonenkov et al., 2005; Xu et al., 2009) that profoundly induces
UCP1 expression in BAT and iWAT (Adams et al., 2012; Ema-
nuelli et al., 2014; Fisher et al., 2012; Hondares et al., 2010;
Lee et al., 2014a). FGF21 signals via FGF receptor 1c and a cor-
eceptor b-klotho (Foltz et al., 2012) expressed in BAT and iWAT
(Ito et al., 2000). FGF21 is induced and secreted by rodent and
human BAT upon thermogenic stimulation (Fisher et al., 2012;
Hondares et al., 2011, 2014; Lee et al., 2014b; Sharp et al.,
2012). It leads to iWAT browning and brite adipocyte appear-
ance (Fisher et al., 2012), suggesting a critical role of brite adi-
pocytes and UCP1 in eliciting its pharmacologic effect. FGF21
signaling in WAT is required for improvement of metabolic pa-
rameters such as body weight, glucose homeostasis, and
plasma triglycerides (Ve´niant et al., 2012; Wu et al., 2011).
The preservation of FGF21’s metabolic effects in mice without
interscapular BAT implicates iWAT brite adipocytes in FGF21-
mediated antiobesogenic and antidiabetic actions (Emanuelli
et al., 2014).
Although the primary role of BAT is thermogenesis, the
outcome is an increase in energy expenditure. Pharmacologic
BAT activation and metabolic inefficiency could improve condi-
tions such as obesity; indeed, much research is now directed to-
ward this area (Chechi et al., 2014; Sammons and Price, 2014).
FGF21 has become a paradigm for UCP1 activation and brite
adipocyte induction as a therapeutic strategy for obesity and
diabetes. Given this growing interest, we examined the impor-
tance of brite adipocytes as antiobesity agents by evaluating
their requirement for eliciting FGF21-induced weight loss and
antidiabetic effects.
RESULTS AND DISCUSSION
FGF21-Fc Is Efficacious in Lean andDiet-InducedObese
Mice Housed in a Thermoneutral Environment
Thermoneutral zone (TNZ) housing (30C) suppresses sympa-
thetic tone andBAT-induced thermogenesis inmice, whereas in-
dustry-standard housing (21C) activates BAT and brite adipose.
Housing temperature can alter the effect of BAT-related factors
such as bone morphogenetic protein 7 (Boon et al., 2013). Toell Metabolism 21, 731–738, May 5, 2015 ª2015 Elsevier Inc. 731
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study the dependence of FGF21’s effects on housing tempera-
ture and BAT/brite activity, we assessed two doses (submaximal
and maximal) of a long-acting FGF21 analog, FGF21-Fc, in lean
and diet-induced obese (DIO) mice housed in both environments
(Figure 1). First we established and characterized treatment-
naive lean and DIO mice at 21C and 30C (Animal Study Design
I stage 1). Body weight, glucose tolerance, and insulin levels did
not differ in both groups in either environment (see Table S1
available online), but BAT histology differed. BAT adipocytes
were uniformly multilocular in leanmice at 21C but primarily uni-
locular (>90%) in leanmice at 30C (Figure S1). DIOmice at 21C
had equally distributed uni- and multilocular BAT adipocytes,
whereas DIO mice at 30C had primarily unilocular (>90%)
BAT. iWAT adipocyte morphology did not differ between lean
and DIO mice at either 21C or 30C.
After 15 days of FGF21-Fc treatment (Animal Study Design I
stage 2), body weight, insulin/glucose levels, and glucose toler-
ance (hereafter termed beneficial effects) similarly improved in
lean and DIOmice at 21C or 30C (Figures 1A–1H), and BAT ad-
ipocytes were uniformly multilocular (Figures 1I and 1J). In
contrast, a temperature-dependent increase was seen in the
number of individual and aggregates of multilocular brite adipo-
cytes in iWAT of FGF21-Fc-treated lean mice. Most (seven of
eight) of these mice housed at 21C showed several variably
sized brite adipocyte aggregates in iWAT, along with isolated
cells (Figure 1K, inset; Table S2). Brite adipocyte appearance
was substantially less at 30C (Figure 1K). In contrast, iWAT of
DIO mice at either 21C or 30C had microscopically identical
isolated, rare (<1%), multilocular brite adipocytes with or without
FGF21-Fc treatment (Figure 1L; Table S2). Thus, FGF21-Fc’s
beneficial effects occurred without multilocularity in iWAT, sug-
gestingmultilocular adipocyte activation in iWAT is of little signif-
icance in eliciting its beneficial effects.
To confirm the molecular extent of browning and multilocular
cell appearance in iWAT of FGF21-Fc-treated mice, we as-
sessed UCP1 protein induction in BAT and iWAT lysates from
vehicle- and FGF21-Fc-treated lean and DIO mice housed in
both environments. BAT of FGF21-Fc-treated lean (Figure 1M)
and DIO (Figure 1N) mice at 21C showed robust UCP1 expres-
sion; the induction was more modest at 30C. In contrast, UCP1
induction by FGF21-Fc in iWAT was observed only in lean mice
at 21C (Figures 1M and 1N). UCP1 was below detection limit in
iWAT of vehicle-treated lean mice and vehicle- and FGF21-Fc-
treated DIO mice housed at both temperatures.Figure 1. FGF21-Fc Is Efficacious in Lean and DIO Mice Housed in Sta
(A–D) Chow-fed, leanmice housed at 21Cor 30Cwere treatedwith vehicle or 3m
over 15 days, plasma glucose and insulin levels were measured on days 0 and 1
(E–H) DIOmice housed at 21C or 30Cwere treated with 0.5 or 3mg/kg human FG
levels were measured on days 0 and 11, and glucose tolerance was assessed o
(I) BAT morphology (H&E) of lean mice from (A)–(D). Bars represent 200 mm.
(J) BAT morphology (H&E) of DIO mice from (E)–(H). Bars represent 200 mm.
(K) iWAT morphology (H&E) of lean mice from (A)–(D). Bars represent 200 mm.
represent 100 mm.
(L) iWAT morphology (H&E) of DIO mice from (E)–(H). Bars represent 200 mm.
(M and N) BAT and iWAT were excised from lean and DIO mice after completion
immunoblot for UCP1. A BAT lysate from a wild-type C57BL/6 mouse was used
(arrow). a/b-tubulin was used as a loading control.
Data represent mean ± SEM (n = 8/group), analyzed by ANCOVA. *p < 0.05, **p
Tables S1 and S2.
CThese data support our histologic findings that FGF21-Fc in-
duces brite adipocytes and UCP1 in lean mice at 21C but not
in lean mice at 30C or DIO mice at either temperature. Lack of
detectable UCP1 induction in iWAT alongside FGF21-Fc’s ef-
fects in these mice extends the finding that not only brite adipo-
cyte expansion but also UCP1 expression can be dissociated
from FGF21-Fc’s beneficial effects.
FGF21-Fc Is Equally Beneficial in Ucp1–/– Mice
The link between FGF21-Fc’s beneficial effects and UCP1 in-
duction was further studied in Ucp1/ mice. To relieve thermal
stress, a colony of Ucp1/ mice was raised at 30C (Feldmann
et al., 2009), which showed no overt phenotype differences
versus control Ucp1+/ mice in these conditions (Table S3),
consistent with previous reports (Enerba¨ck et al., 1997).
Ucp1+/ and Ucp1/ mice were treated with vehicle or
FGF21-Fc for 17 days, and established endpoints (Xu et al.,
2009) were assessed. Control mice had 18% lower body weight
and 78% and 23% lower plasma insulin and glucose levels,
respectively (Figures 2A–2C); glucose tolerance was improved
(33% lower area under the curve [AUC]; Figure 2D). Given the
increased UCP1 expression in iWAT of lean mice post-FGF21-
Fc treatment (Figure 1M) (Fisher et al., 2012), we expected a
diminished beneficial effect in FGF21-Fc-treated Ucp1/
mice. Surprisingly, the beneficial effects in these mice were
similar to those observed in Ucp1+/ mice: 14% lower body
weight; 70% and 6% lower plasma insulin and glucose levels,
respectively; and 30% lower glucose tolerance AUC (Figures
2A–2D). Glucose level was not significantly reduced by
FGF21-Fc in Ucp1/ mice, but was significantly lower at
glucose tolerance test (GTT; Figure 2D) initiation, confirming
improved glucose homeostasis in these mice. Equal improve-
ment in plasma lipids was seen in both mouse strains (Figures
2E–2G). UCP1 absence in iWAT and BAT of Ucp1/ mice
housed at 30C was confirmed by immunoblot analysis (Fig-
ure 2H). UCP1 expression in BAT and iWAT of Ucp1+/ mice
housed at 30C was suppressed as brite adipocytes are not
induced in TNZ environments. FGF21-Fc led to UCP1 induction
in BAT of Ucp1+/ mice. As expected, UCP1 was absent in
Ucp1/mice with or without exposure to FGF21-Fc, confirming
the genotype of the mice. These data suggest that although
FGF21-Fc influences UCP1 expression, energy dissipation via
UCP1-mediated uncoupling does not account for its beneficial
effect.ndard or Thermoneutral Environments
g/kg human FGF21-Fc per Animal Study Design I. Bodyweight wasmonitored
2, and glucose tolerance was assessed on day 15.
F21-Fc. Body weight wasmonitored over 15 days, plasma glucose and insulin
n day 15.
Inset (red box) shows higher magnification of multilocular adipocytes. Bars
of Animal Study Design I, and two lysates from each group were analyzed by
as a positive control to highlight a nonspecific immunoreactive band in iWAT
< 0.01, ***p < 0.001 versus vehicle control. See also Figures S1 and S2 and
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Figure 2. FGF21-Fc Is Efficacious in Ucp1–/– Mice
(A–G)Ucp1+/ andUcp1/mice housed at 30Cwere treated with vehicle or 3mg/kg human FGF21-Fc as described in Animal Study Design II. Body weight was
monitored over 15 days; plasma glucose, insulin, cholesterol, triglycerides, and NEFA were measured on days 0 and 11; and glucose tolerance was assessed on
day 15. Data represent mean ± SEM (n = 4–6 mice/group), analyzed by ANCOVA. *p < 0.05, **p < 0.01, ***p < 0.001 versus vehicle control.
(H) Immunoblot analysis of BAT and iWAT lysates (two from each group) fromUcp1+/ andUcp1/mice treatedwith human FGF21-Fc. A BAT lysate from awild-
type C57BL/6 mouse was used as a positive control to highlight a nonspecific band (arrow). a/b-tubulin was used as a loading control. See also Table S3.FGF21-Fc Increases Energy Expenditure inUcp1–/– Mice
FGF21 increases energy expenditure in DIO mice housed at
21C (Xu et al., 2009). To explore the possible reason for
FGF21-Fc’s beneficial effects in Ucp1/ mice, we conducted
food intake and indirect calorimetry studies. First we established
reproducibility of FGF21-Fc’s effects on body weight in Ucp1+/
and Ucp1/ mice (Figure 3A). Reduced food intake was not
responsible for weight loss; in fact, when standardized to body
weight, FGF21-Fc increased food intake in Ucp1/ mice, with
similar trends in Ucp1+/ mice (Figure 3B). In contrast, O2 con-
sumption and CO2 production dramatically increased (Figures
3C and 3D). This effect was more significant in Ucp1+/ mice,
indicating a slightly diminished FGF21-Fc effect in Ucp1/
mice. Substrate oxidation preference, inferred from respiratory
exchange ratio, was unchanged in all FGF21-Fc-treated mice
(Figure 3E). FGF21-Fc did not alter physical activity in Ucp1+/
mice but mildly increased it in Ucp1/mice during the day (Fig-
ure 3F). These data support the fact that FGF21-Fc-induced
weight loss is caused not by changes in food intake or specific734 Cell Metabolism 21, 731–738, May 5, 2015 ª2015 Elsevier Inc.increases in substrate utilization but by increases in energy
expenditure in Ucp1+/ and Ucp1/ mice.
FGF21-Fc-Induced Gene Expression Changes inUcp1+/–
and Ucp1–/– Mice
Although UCP1 is established as the predominant thermogenic
protein (Nedergaard et al., 2001), we assayed possible compen-
sation by UCP2/3 (Figure 4). First we observed that FGF21-Fc
induced Ucp1 expression in Ucp1+/ BAT and iWAT. Notably,
this was not detected at the protein level in iWAT (Figure 2H), pre-
sumably owing to the higher sensitivity of the RT-PCR technique.
Ucp1was undetectable in iWAT of vehicle-treatedUcp1+/mice
and prevented calculation of a fold change from vehicle- to
FGF21-Fc-treated mice. As expected, Ucp1 was undetectable
in Ucp1/mice; however, an outlier was identified, highlighted,
and excluded from statistical analyses. Ucp2 expression in adi-
pose tissue of Ucp1+/ and Ucp1/mice was mostly unaltered
by FGF21-Fc, though reduced expression was observed in BAT
of Ucp1+/ mice. This reduction was Ucp1 dependent and
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Figure 3. Increased Energy Expenditure in
FGF21-Fc-Treated Ucp1–/– Mice
(A–F) Ucp1+/ and Ucp1/ mice housed at 30C
were treated with vehicle or 3 mg/kg human
FGF21-Fc per Animal Study Design II while
housed in indirect calorimetry chambers. Body
weight and food intake were monitored over
15 days; O2 consumption (VO2), CO2 production
(VCO2), respiratory exchange ratio, and physical
activity were monitored on day and night 5. Data
represent mean ± SEM (n = 4mice/group) of actual
data (A and B) or whole day and night averages
(C–F), analyzed by ANCOVA. *p < 0.05, **p < 0.01,
***p < 0.001 versus vehicle control of same geno-
type; ns, nonsignificant.unlikely to account for any compensation of UCP1 deficiency, as
it was not seen in BAT of Ucp1/mice. Further, the expression
pattern was not repeated in iWAT. Ucp3 expression was unal-
tered in BAT and iWAT of FGF21-Fc-treated mice.
FGF21 has been shown to induce the mitochondrial biogen-
esis regulator peroxisome proliferator-activated receptor
gamma coactivator 1a (PGC-1a) (Chau et al., 2010; Potthoff
et al., 2009). In our study, Ppargc1 expression was not increased
in BAT of FGF21-Fc-treated Ucp1+/ mice, consistent with pre-
vious reports (Fisher et al., 2012); however, it was significantly
increased in BAT of FGF21-Fc-treated Ucp1/ mice, suggest-
ing possible adaptation toUcp1 deficiency only in the challenged
state. Importantly, Ppargc1 expression was upregulated (1.75-
to 2-fold) in iWAT of FGF21-Fc-treated mice of both genotypes
(Figure 4). This is consistent with other studies (Chau et al.,
2010; Coskun et al., 2008; Fisher et al., 2012) and shows that
PGC-1a induction, while moderate, is more coincident with
FGF21-Fc-induced beneficial effects than Ucp1 upregulation,
suggesting that specifically in adipose tissue, mitochondrial
biogenesis and thus mitochondrial function is related to theCell Metabolism 21, 731observed weight loss. FGF21 has been
shown to increase oxidative capacity in
3T3-L1 cells, and this effect is dependent
on PGC-1a (Chau et al., 2010). Our study
noted increased O2 consumption by
FGF21-Fc-treated Ucp1/ mice. In vitro
data show similar increases in O2 con-
sumption (Chau et al., 2010), suggesting
that minimal changes in Ppargc1 expres-
sion in vivo (Figure 4) may underlie in-
creases in O2 consumption in Ucp1
/
mice. This effect is also consistent with
a previous report identifying a relationship
between FGF21 and PGC-1a in the liver
(Potthoff et al., 2009), suggesting that
FGF21-induced regulation of PGC-1a is
a multiorgan response, potentially under-
lying the metabolic changes observed
with FGF21 in therapeutic settings. The
precisemechanism of FGF21’s therapeu-
tic effect remains unknown, although we
show increased energy expenditure and
higher Ppargc1 expression that coincideswith increases in body temperature, as noted by Coskun et al.
(2008). This suggests that energy expenditure via increased
body temperature is a potential mechanism of action and is
not associated with brite in iWAT.
Our study confirms FGF21 induction of browning, but dis-
proves the current theory that this event is responsible for its
weight loss and related beneficial effects. Notably, FGF21-Fc
induced significant histologic changes in lean mice at 21C, yet
these are dispensable for its beneficial effects. Thus, either
FGF21-induced brite is a physiologic response for thermal
defense and unrelated to the significant changes in energy
expenditure that coincide with FGF21’s beneficial effects, or
nonshivering thermogenesis and uncoupling are parallel to mito-
chondrial biogenesis and activation and occur downstream of
FGF21’s metabolic effects. A limitation of this study is that brite
activation by FGF21-Fc was assessed by histology and UCP1
presence only and not functionally. Given that cold-adapted
brite mitochondria are functionally thermogenic (Shabalina
et al., 2013) and dependent on UCP1 presence (Nedergaard
et al., 2001), our observations likely indicate a lack of functional–738, May 5, 2015 ª2015 Elsevier Inc. 735
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Figure 4. Gene Expression in iWAT and BAT
of FGF21-Fc-Treated Ucp1–/– Mice
Fold change is expressed relative to vehicle-
treated Ucp1+/ mice, except for iWAT Ucp1
expression, which was only detected in Ucp1+/
FGF21-Fc-treated mice. Data are expressed in
RT-PCR threshold cycles (Ct). An outlier based on
Ucp1 expression was identified, marked with an
empty circle, and excluded from statistical ana-
lyses. Data represent individual values (n = 7–8/
group), analyzed by one-way ANOVA. *p < 0.05,
**p < 0.01, ***p < 0.001 in pairwise comparisons as
indicated; only significant changes are displayed.
See also Table S4.brite in our mouse models, though this needs to be carefully
tested.
In summary, only lean mice housed at 21C showed substan-
tial browning in iWAT post-FGF21-Fc treatment. Browning was
almost absent in lean mice housed at 30C or in DIO mice
housed at 21C or 30C. FGF21-Fc was efficacious in Ucp1/
mice despite UCP1 absence. Further, increased O2 consump-
tion was retained in FGF21-Fc-treated Ucp1/mice, indicating
similar changes in metabolism between genotypes and environ-
ments. We propose that FGF21-induced browning in iWAT is not
causative of weight loss.
EXPERIMENTAL PROCEDURES
Animal Procedures
Male mice (see Animal Design I–II for strain and genotype) were cared for in
accordance with the Guide for the Care and Use of Laboratory Animals, 8th
Edition.Mice were singly housed in an AAALAC-accredited facility in ventilated
static housingwith corn cob bedding. All research protocols were approved by
the Institutional Animal Care and Use Committee. Blood samples were
collected from the retro-orbital sinus of conscious mice into EDTA tubes to736 Cell Metabolism 21, 731–738, May 5, 2015 ª2015 Elsevier Inc.determine blood glucose levels (AlphaTRAK gluc-
ometer, Abbott Animal Health, Abbott Park, IL).
GTT was done after intraperitoneal injection of 2
g/kg glucose in mice fasted for 6 hr. Plasma
cholesterol, triglyceride, and nonesterified fatty
acid (NEFA) levels were measured using the
Olympus AU400e Chemistry Analyzer (Olympus
America, Inc, Center Valley, PA); insulin levels
were determined by ELISA (Alpco, Salem, NH).
Recombinant human FGF21 and long-acting hu-
man FGF21-Fc were generated as previously
described (Hecht et al., 2012).
Animal Study Design I: FGF21-Fc
Treatment in Lean and DIO Mice Housed
in Standard and TNZ Environments
In stage 1, 4-week-old male C57BL/6 mice (Harlan
Labs, Indiana, IN) were housed at 21C or 30C
and fed standard chow (2020X, Harlan Labs) or
high-fat diets (Research Diets, D12492) for 10 or
13 weeks, respectively. Blood samples were
collected before study initiation to establish base-
line values for each endpoint.
In stage 2, mice were treated with vehicle or
FGF21-Fc (n = 8/group). Intraperitoneal injections
of vehicle, 0.5 mg/kg (DIO only) FGF21-Fc, or
3 mg/kg FGF21-Fc were administered every3 days for 15 days. Plasma was collected on day 11 or 12 and GTT done on
day 15 post-treatment initiation. At necropsy, plasma, iWAT, and BAT were
collected for storage in liquid nitrogen or fixation in 10% neutral-buffered
formalin.
Animal Study Design II: FGF21-Fc Treatment in Ucp1–/– Mice
MaleUcp1+/ andUcp1/ (Stock 3124, The Jackson Laboratory, Bar Harbor,
ME) mice (age 21–27 weeks) were singly housed at 30C and fed standard
chow (2020X, Harlan Labs). Blood samples were collected before study initia-
tion to establish baseline values for each endpoint. Mice were administered
either vehicle or 3 mg/kg FGF21-Fc (n = 4–6/group) every 3 days for
15 days. Plasma was collected on day 11. GTT was done 15 days post-treat-
ment initiation. At necropsy (day 17), plasma, iWAT, and BAT were collected
for storage in liquid nitrogen. For gene expression and indirect calorimetry
assessments, duplicate cohorts of mice (n = 7–8/group, gene expression;
n = 4/group, indirect calorimetry) in similar age ranges received the same treat-
ment regimen. Mice were acclimated to metabolic cages at 30C (Columbus
Instruments, Columbus, OH) before treatment initiation. Data were analyzed
after 5 days of treatment.
Histopathology and UCP1 Immunohistochemistry
BAT and iWAT were fixed for 72 hr in 10% neutral-buffered formalin. All tissues
were embedded in paraffin, sectioned at 5 mm, and stained with hematoxylin
and eosin (H&E). For UCP1 immunohistochemistry (IHC), the Abcam ab10983
polyclonal antibody was selected as a primary antibody after extensive
screening of antibody candidates in BAT and iWAT using IHC-specific condi-
tions. Staining specificity by ab10983 was confirmed by assessing UCP1
staining in BAT and iWAT of wild-type, as well as control Ucp1+/ and
Ucp1/ mice. After IHC protocol optimization, 5 mm iWAT sections were de-
paraffinized, hydrated with deionized water, and pretreated with DIVA (catalog
number DV2004G1, Biocare, Concord, CA) antigen retrieval solution in a pres-
sure cooker for 40 min. Sections were blocked with CAS block (catalog
number 008120, Invitrogen, Camarillo, CA) to reduce or prevent nonspecific
staining. Slideswere incubatedwith rabbit polyclonal anti-UCP1 (catalog num-
ber ab10983, Abcam, Cambridge, MA) at 1:1,000 for 1 hr at room temperature
and quenched with 3% H2O2. UCP1 was detected using the EnVision+ Sys-
tem-HRP labeled polymer anti-rabbit kit (catalog number K4003, DAKO,
Carpinteria, CA) followed by visualization with DAB (catalog number K3468,
DAKO). Sections were counterstained with hematoxylin. Semiquantitative
grading was conducted by light microscopic evaluation of H&E and replicate
UCP1 immunostained iWAT sections from all mice. Each iWAT sample was
scored on a four-point grading scale based on the number of multilocular cells
(singly or in aggregate) showing specific UCP1 intracellular staining (definitions
and photomicrographic examples in Figure S2).
RNA Analysis
RNA was prepared using the QIAGEN RNeasy Mini Kit and analyzed with the
QIAGEN RT-PCR Multiplexing system on an ABI Prism 7900 (Applied Bio-
systems, Foster City, CA). Oligonucleotide and probe sequences are shown
in Table S4. Each reaction was carried out with 50 ng total RNA using
400 nM oligonucleotides and a 200 nM probe. Each RNA sample was run in
triplicate, and Ppia was used as the housekeeping gene.
Immunoblot Analysis
Mechanically lysed tissues were collected in lysis buffer (catalog number
FNN0021, Invitrogen) containing 1 mM phenylmethylsulfonyl fluoride and pro-
tease inhibitor (catalog number 04 693 132 001, Roche), held for 30min on ice,
and vortexed every 10 min. Lysates were then centrifuged at 500 3 g for
10 min at 4C. Equal amounts of proteins were separated by SDS-PAGE
and transferred to nitrocellulose membranes. Membranes were blocked
with 5% milk in 0.1% Tween-20 in PBS overnight at 4C. Primary (UCP1, cat-
alog number ab10983, Abcam; a/b-tubulin, catalog number 2148S, Cell
Signaling) and secondary (catalog number 31460, Thermo Scientific) anti-
bodies were incubated for 1 hr at room temperature. Specifically bound anti-
bodies were detected using chemiluminescent substrate (catalog number
34080, Thermo Scientific).
Statistical Analyses
Analysis of covariance (ANCOVA) was performed at each time point with the
baseline value as covariate if available. For gene expression analyses, a
one-way analysis of variance (ANOVA) was performed with a Tukey post hoc
test. The p value for pairwise comparisons is presented when the overall group
effect is statistically significant (p < 0.05). Where only two groups of data were
compared, an unpaired two-tailed t test was used. Figures display SEM.SUPPLEMENTAL INFORMATION
Supplemental Information includes two figures and four tables and can be
found with this article at http://dx.doi.org/10.1016/j.cmet.2015.04.019.
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